Clinical trials: Molecular Targeted Therapies
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with…
- Trial name
- Carolyn-USA (NCT07049055)
- Testing
- E-EDV-D682, EDV-GC, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Engeneic Pty Limited
Brain Neuroimaging Biomarkers in Huntington Disease
Dynamic Neuroimaging Biomarkers in Huntington's Disease
There is no curative treatment available today in Huntington disease (HD) despite the identification of the mutated gene 20 years ago.
- Trial name
- HDeNERGY (NCT02639871)
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumors, Ovarian Cancer
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT02476955
- Testing
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
Haematological Malignancy, Solid Tumour
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation.
- Trial name
- DETERMINE (NCT05722886)
- Testing
- Alectinib, Atezolizumab, Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 825 people
- Sponsor
- Cancer Research UK
Solid Tumor, Metastatic Cancer
A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre
The project, called "BALLETT" (Belgian Approach of Local Laboratory Extensive Tumor Testing), has a double goal: (1) show the relevance of broad molecular profiling to improve oncological patients care, (2) demonstrate that broad…
- Trial name
- BALLETT (NCT05058937)
- Testing
- Comprehensive genomic profiling
- Where
- 12 sites in Belgium
- Volunteers
- 936 people
- Sponsor
- The Belgian Society of Medical Oncology
Hepatocellular Carcinoma
Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers
The purpose of this study is to id transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular targeted therapies in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCEsub (NCT05278195)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations.
- Trial name
- AURORAS-1 (NCT06983743)
- Testing
- ERAS-0015, ERAS-0015 in combination
- Where
- 9 sites in United States
- Volunteers
- 600 people
- Sponsor
- Erasca, Inc.
Hepatocellular Carcinoma, Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
- Trial name
- NCT01482520
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage…
- Trial name
- CHANCE2202 (NCT05332496)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 941 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Rhabdomyosarcoma
Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry
This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment…
- Trial name
- AERO-RMS (NCT06924463)
- Testing
- None AHT
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Lille University
Epithelial Ovarian Cancer, Ovarian Cancer
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
- Trial name
- POLO (NCT05187208)
- Testing
- Niraparib
- Volunteers
- 102 people
- Sponsor
- Seoul National University Hospital
Lung Neoplasms
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
This is a non-interventional multi-center with investigational sites in Chile and Brasil diagnostic study to validate novel diagnostic technologies, such as Next Generation Sequencing (NGS) from both tissue and blood compared to…
- Trial name
- NIRVANA (NCT03220230)
- Where
- 37 sites in Brazil, Chile and 1 more
- Volunteers
- 4,240 people
- Sponsor
- Pfizer
Mouth Neoplasms, Neoadjuvant Therapy
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
Exploring the Safety and Efficacy of Benmelstobart Combined with Anlotinib and Chemotherapy as Neoadjuvant Therapy Followed by Surgery and Postoperative Radiotherapy in Patients with Locally Advanced Oral Cancer This is a…
- Conditions
- Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT06848439
- Testing
- benmelstobart-Anlotinib-Chemo
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Head and Neck Cancer
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898742
- Testing
- DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
- Trial name
- NCT02597179
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Bevacizumab
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
- Conditions
- Breast Cancer, Bevacizumab, Neoadjuvant Chemotherapy, Molecular Targeted Therapy
- Trial name
- BIBC (NCT01652560)
- Testing
- bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- LiNanlin,Ph.D, Chief Physician,Clinical Professor
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Breast Cancer
Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
The purpose of this study is to see what kinds of breast tumors will respond to lapatinib. Lapatinib is an experimental medicine which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00343759
- Testing
- Lapatinib
- Where
- United States
- Sponsor
- University of Pennsylvania